Celltrion said that the Indonesian drug regulator granted emergency use authorization (EUA) for its Covid-19 antibody treatment, Regkirona, last Saturday.

Celltrion’s Covid-19 antibody treatment, Regkirona, has received emergency use authorization from the Indonesian drug regulator.
Celltrion’s Covid-19 antibody treatment, Regkirona, has received emergency use authorization from the Indonesian drug regulator.

The Indonesian food and drug safety agency, known by the acronym of BPOM, announced that it would approve the use of Regkirona on high-risk adult patients with mild and moderate Covid-19 symptoms.

According to Worldometer, a website for real-time Covid-19 statistics, Indonesia has recorded the cumulative Covid-19 caseload of 2.88 million as of Monday, including 73,600 deaths, replacing India as a new global epicenter of Covid-19.

Celltrion recently confirmed the ability of Regkirona to neutralize the Delta variant in animal tests, expecting that the treatment will be of great help in preventing the spread of the novel coronavirus in Indonesia.

“Regkirona has proven its efficacy through global clinical and quality data and has obtained EUA from the Indonesian government,” a company official said. “The authorization is expected to speed up Regkirona’s export negotiations.”

Copyright © KBR Unauthorized reproduction, redistribution prohibited